Adjuvant nivolumab for the management of pathological residual disease in esophageal or junctional tumors: a word of caution.

Garg, P K; Kumar, R; Dixit, P

Garg, P K; Kumar, R; Dixit, P.

Afiliação

Garg PK; Department of Surgical Oncology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, India. Electronic address: dr.pankajgarg@gmail.com.
Kumar R; Department of Surgical Oncology, All India Institute of Medical Sciences, Rishikesh, India.
Dixit P; Department of Gastroenterology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, India.

Ann Oncol ; 32(9): 1189-1190, 2021 09.

Article em En | MEDLINE | ID: mdl-33957223

Assuntos

Antineoplásicos Imunológicos; Nivolumabe; Antineoplásicos Imunológicos/efeitos adversos; Esôfago; Humanos; Neoplasia Residual; Nivolumabe/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Nivolumabe Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google